tbuckley/cabot-search huggingface dataset:
Bowel Disease after Radiotherapy
Authors: Philip F Schofield, D Holden, N D Carr
Journal: Journal of the Royal Society of Medicine (1983)

The clinical presentation, operative findings and outcome in 40 patients who required surgery for bowel disease after radiotherapy are presented. The type of presentation varied according to the time after radiotherapy. In the first month, many patients had a proctitis but none required surgery. Five patients were operated on within one month, 2 for radiation-induced acute ileitis and 3 for exacerbations of pre-existing disease (diverticular disease 2, ulcerative colitis 1). The commonest time of presentation was between 3 and 18 months after radiotherapy, when 20 patients needed surgery for bowel disease caused by radiation-induced local ischaemia. Twelve of these patients had chronic perforation, 6 had severe rectal bleeding and 2 had painful anorectal ulceration. Fifteen patients presented between 2 and 24 years after radiotherapy, usually with incomplete intestinal obstruction due to a fibrous stricture, but 2 patients had rectal carcinoma. Wide resection of the involved bowel was the principal method of treatment but any anastomosis was protected by a proximal defunctioning stoma. There was no operative mortality but 10 patients have died subsequently. The danger of dismissing these patients as having incurable malignancy is stressed because, although the condition is infrequent, it is usually amenable to adequate surgery.
Chimpanzees and Humans: Not So Close?
Authors: Tracy Hampton
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A case of Pyemotes dermatitis.
Authors: MARK HEWITT, G.I. BARROW, D.C. MILLER, S.M. TURK
Journal: British Journal of Dermatology (1976)

Acute dermatitis developed in a fisherman after contact with old cherry-wood. A Pyemotes mite, probably P. beckeri, found in the wood, was thought to be responsible--thus illustrating the importance of appropriate laboratory examinations for ectoparasites. Human skin erruptions caused by indigenous, in contrast to imported, Pyemotes species have not previously been reported in Britain. These tarsonemoid mites attack small insect hosts and their possible role in dermatoses is discussed. Dermatitis caused by these mites is probably world-wide in distribution, but during the last century the confusing acarological nomenclature surrounding Pyemotes has resulted in an equally confusing variety of dermatological diagnoses.
400. Transduction of Human Embryonic Stem Cells with Lentiviral Vectors: Variable Promoter Activity in Pluripotent Cells
Authors: Andrew Hinton, Theodore Friedmann, Alberto Hayek
Journal: Molecular Therapy (2004)

The development of cell and organ-based therapies is hampered by the generally inadequate supply of donor tissues. A potential alternative source of renewable cells is represented by cells such as human embryonic stem cells that can be isolated, grown in culture and differentiated into any desired cell type for regenerative therapy. One approach to carrying out such lineage-specific differentiation steps in such cells involves the transfer and expression of foreign genes which drive cellular differentiation in desired directions. For this purpose it is important to characterize the methods for transduction or other gene transfer at various states of differentiation of target cells. Murine embryonic stem cell (mESC) lines have been studied for many years, whereas human embryonic stem cells were only established recently. However, it is already apparent that some characteristics of hESCs are not shared with mESCs. For example, mESCs can be maintained in a pluripotent state by adding activators of the STAT3 pathway (LIF). Our lab has shown that maintenance of hESC pluripotency relies upon as yet unidentified signal(s) from conditioned medium that act independently of the STAT3 pathway. Thus it is likely that some different genetic patterns are in place within the pluripotent cells of each species. We have examined the properties of the HSF6 and HES3 human embryonic stem cell lines after transduction with a variety of viral vectors and have found optimal gene transfer and reporter transgene expression to occur with HIV-based lentiviral vectors containing the cis-acting elements such as central polypurine tract (cPPT) and constitutively active promoters. Our preliminary data indicate that the strong CMV viral promoter does not drive efficient transgene expression in undifferentiated embryonic stem cells in culture but can express reporter genes efficiently following in vitro cellular differentiation. In contrast, the housekeeping elongation factor 1 alpha (EF1a) promoter drives efficient expression of the reporter GFP gene regardless of the state of cellular differentiation.
Natural History of Early Localized Prostate Cancer—Reply
Authors: Jan-Erik Johansson, Ove Andrén, Swen-Olof Andersson, Anders Magnusson, Paul W. Dickman, Lars Holmberg, Hans-Olov Adami
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector
Authors: Valérie Dardalhon, Sara Jaleco, Cosette Rebouissou, Christophe Ferrand, Nadia Skander, Louise Swainson, Pierre Tiberghien, Hergen Spits, Nelly Noraz, Naomi Taylor
Journal: Blood (2000)
Abstract 263: Changes in Cerebral Oxygen Metabolism and Hemodynamics During ECPR with Therapeutic Hypothermia Measured by Near Infrared Spectroscopy
Authors: Tsuyoshi Kawamorita, Tsukasa Yagi, Taketomo Soga, Harumi Hirose, Kazuhiro Watanabe, Kimio Kikushima, Atsuo Yoshino, Kaoru Sakatani, Ken Nagao
Journal: Circulation (2012)

(Background) For protection of the brain, hypothermia is a helpful therapeutic approach in patients who remain comatose after return of spontaneous circulation (ROSC). The 2010 CPR Guidelines recommend that extracorporeal cardiopulmonary resuscitation (ECPR) using an emergency cardiopulmonary bypass (CPB) should be considered for patients with cardiac arrest. However, it is not yet clear whether this therapy can improve cerebral circulation and oxygenation in these patients. To clarify this issue, we evaluated change of cerebral blood oxygenation (CBO) during ECPR using near-infrared spectroscopy (NIRS). (Methods) Between November 2009 and June 2011, we employed NIRS (NIRO-200NX, Hamamatsu Photonics, Japan) to measure CBO in the bilateral frontal lobe in patients transported to the ER after out-of-hospital cardiac arrest. Enrollment criteria were: aged 18-74 years; cardiac arrest witnessed by bystanders; presumed cardiac etiology of cardiac arrest according to the Utstein style guidelines; estimated time interval from collapse to paramedic’s arrival at patient’s side within 15 min; defibrillation using automated external defibrillator by bystander and/or emergency medical personnel; and persistent cardiac arrest on arrival at the ER. (Results) Fifteen patients met the above criteria. The tissue oxygenation index (TOI) on arrival at the ER was 36.5%. This increased to 67.8% during ECPR (P&lt;0.001). The patients whose TOI subsequently decreased had a favourable neurological outcome (figure). (Conclusion) The increase of TOI during ECPR might reflect an improvement in cerebral blood flow, while the decrease of TOI after ECPR might reflect oxygen utilization of the brain tissue as a result of neuronal cell survival. NIRS may be useful for monitoring cerebral hemodynamics and oxygen metabolism during CPR.
Abstract 18157: Presence of Calmodulin Potentiates Block of Ryanodine Receptor Calcium Release Channels by Dantrolene and Flecainide
Authors: Nieves Gomez-Hurtado, Ye Win Oo, Derek Laver, Bjorn Knollmann
Journal: Circulation (2014)

Introduction:  Dantrolene and flecainide have been used to suppress ventricular arrhythmias caused by spontaneous Ca release from the sarcroplasmic reticulum in animal models and humans. Since both agents exhibit much lower potency against single RyR2 Ca release channels in vitro, whether RyR2 block contributes to their antiarrhythmic mechanism of action has remained controversial.   Hypothesis:  Loss of Calmodulin (CaM), a physiological binding partner of RyR2, is responsible for the discrepancy of in vivo and in vitro results.   Methods and Results:  Using single channels isolated from sheep hearts and incorporated into lipid bilayers, we constructed concentration-response curves of dantrolene and flecainide in the presence and absence of physiological concentrations (100nM) of CaM. Without CaM, dantrolene (up to 100 μM) had no effect on single channel open probability (Po). In presence of CaM, dantrolene inhibited single RyR2 channels with an IC50 of 0.2 μM, and a maximum inhibitory effect (Emax) of 50%. Likewise, CaM also potentiated the action of flecainide on single RyR2 channels, with 3-fold increase in potency (i.e. lower IC50, Figure) and a modest increase in Emax (Figure). We next tested dantrolene and flecainide in permeabilized ventricular myocytes isolated from calsequestrin knockout mice, an established genetic model of Ca-release triggered ventricular arrhythmia. Addition of 100 nM CaM significantly increased the potency of dantrolene for suppressing spontaneous Ca wave activity (IC50: Dantrolene = 20 μM; dantrolene+CaM = 6 μM, n= 80 myocytes per group), whereas Emax was unchanged (75% inhibition). CaM doubled both the potency (IC50 increased from 3 μM to 1.4 μM) and efficacy (Emax increased from 40% to 80% inhibition) of Ca wave suppression by flecainide.   Conclusions:  Calmodulin is critical for drug block of RyR2 channels by dantrolene and flecainide.
Digital Information Archiving Policies in High-Impact Medical and Scientific Periodicals
Authors: Lisa M Schilling, Desiree P Kelly, Amanda L Drake, Lauren F Heilig, Eric J Hester, Robert P Dellavalle
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA WITH LANATOSIDE C
Authors: J G BARROW
Journal: Annals of Internal Medicine (1950)

Article1 January 1950TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA WITH LANATOSIDE CJ. GORDON BARROW, M.D.J. GORDON BARROW, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-32-1-116 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince an acute attack of paroxysmal auricular tachycardia may occasionally precipitate heart failure and even death if allowed to persist over long periods of time, it is desirable to terminate each attack as quickly as possible. The drug used should be non-toxic, rapid in its action, and certain in its effect. Unpleasant side effects are to be avoided if possible. Such drugs as quinidine and mecholyl which are commonly used in the treatment of this condition have the disadvantage of both unpleasant side effects and fairly frequent toxic manifestations, nor do they always stop the attack. It was because of...Bibliography1. WeisbergerFeil ASH: Lanatoside C in the treatment of persistent paroxysmal auricular tachycardia, Am. Heart J. 34: 871, 1947. CrossrefMedlineGoogle Scholar2. YoumansGoodmanGould WBMJJ: Neosynephrine in treatment of paroxysmal supraventricular tachycardia, Am. Heart J. 37: 359, 1949. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Atlanta, Georgia*Received for publication June 5, 1948. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byReplyThe effects of ouabain on induction of atrioventricular nodal re-entrant paroxysmal supraventricular tachycardia.Current status of treatment of paroxysmal atrial tachycardiaTherapie der HerzinsuffizienzDie Rhythmusstörungen des Herzens (einschließlich der intramuralen Leitungsstörungen und des Alternans)Paroxysmal supraventricular tachycardias complicating organic heart diseaseThe treatment of auricular arrhythmias with deslanoside∗The Cardiac Arrhythmias: Some Aspects of TreatmentErrors in the Recognition and Treatment of Heart DiseaseThe Cardiac ArrhythmiasPAROXYSMAL AURICULAR TACHYCARDIA: OBSERVATIONS IN 47 CASES*GEORGE M. JONES, M.D., F.A.C.P.Use of pronestyl in the treatment of ectopic rhythmsThe action of acetyl strophanthidin in rapid cardiac arrhythmias 1 January 1950Volume 32, Issue 1Page: 116-119KeywordsAdverse reactionsDrugsHeart failureParoxysmal supraventricular tachycardiaTachycardia ePublished: 1 December 2008 Issue Published: 1 January 1950 PDF downloadLoading ...
Long-term follow-up of initially successful trabeculectomy with 5-fluorouracil injections1 1The authors have no proprietary interest in any of the materials used in this study.
Authors: Ricardo Suzuki, Christopher J Dickens, Andrew G Iwach, H.Dunbar Hoskins, John Hetherington, Richard P Juster, Patricia C Wong, Martha T Klufas, Clifford J Leong, Ngoc Nguyen
Journal: Ophthalmology (2002)
Chemotherapy associated anemia in solid tumor patients from Anatolia
Authors: H. S. Coskun, O. Yilmaz, G. Alanoglu, M. Sahin, E. R. Ozlem, I. Ergurhan Ilhan
Journal: Journal of Clinical Oncology (2005)

8257 Background: Chemotherapy (CT) induced anemia is a delayed toxicity of sistemic treatmet. In this study, we explored anemia in Turkish patients received CT. Methods: Eighty-two patients who completed first line CT enrolled into study. All patients were treated with combination CT; ECOG PS was 0 or 1. Patients were divided into 4 groups according to dominant CT drugs as follows cisplatin, fluorouracil (FU), taxanes and anthracycline. Patients received more than one dominant drug excluded from study. Results: Patients were distributed according to CT groups as follows; 29 (35.4%) in FU group, 28 (34.1%) in anthracycline group, 17 (20.7%) in cisplatin group, 8 (9.8%) in taxanes group. Median age was 59 years (range 35–80). Forty patients (48.8%) were female, 42 (51.2%) male. Primary diagnosis was as follows, breast cancer 22 (26.8%), colorectal cancer 16 (19.5%), lung cancer 12 (14.6%), lymphoma 9 (11.0%), gastric cancer 7 (8.5%), and unknown primary origin of metastatic carcinoma 4 (4.9%) and others 12 (14.7%). Patients received CT between 1 to 6 cycles (median 4). Before chemotherapy the median Hemoglobin (Hb) level was 12.3g/dl (8.8–16.7) and the median haemotocrit level was %36.5 (%27.7–49.1). Median Hb levels median were similar between the four groups before chemotherapy. After CT median of Hb levels was 11.5 g/dl in all groups. Difference between Hb levels before and after CT was statistically significant (p=0.001). Median Hb levels before and after the CT were as follows; in the FU 12.6 g/dl (10.1–14.9) and 11.8 g/dl (8.3–15.5) (p=0.08), in the anthracycline 12.0 g/dl (8.8–15.6) and 11.5 g/dl (9.5–15.2) (p=0.02), in the cisplatin 12.7 g/dl (10.1–16.7) and 10.2 g/dl (7.3–12.7) (p=0.002), in the taxane 12.1 g/dl (11.8–13.3) and 11.6 g/dl (9.0–13.8) (p=0.26) respectively. The decreases in Hb levels were seen at all groups but the most severe decrement was detected at the cisplatin group. The Hb level decrement was statistically significant in the cisplatin and anthracycline groups but it was not significant in the FU and taxane groups. Conclusions: CT associated anemia is frequent and accompanies especially the protocols consisting cisplatin and anthracyline in Turkish patients with solid tumors. No significant financial relationships to disclose.
Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria
Authors: Johannes N. Spelbrink, Fang-Yuan Li, Valeria Tiranti, Kaisu Nikali, Qiu-Ping Yuan, Muhammed Tariq, Sjoerd Wanrooij, Nuria Garrido, Giacomo Comi, Lucia Morandi, Lucio Santoro, Antonio Toscano, Gian-Maria Fabrizi, Hannu Somer, Rebecca Croxen, David Beeson, Joanna Poulton, Anu Suomalainen, Howard T Jacobs, Massimo Zeviani, Catharina Larsson
Journal: Nature Genetics (2001)
Abstract 2848: Urinary prostaglandin E metabolite as a biomarker predicting response to EGFR therapy in patients with head and neck cancer
Authors: Vikram D. Kekatpure, Amritha Suresh, Bharath Rangarajan, Gangotri Siddappa, Moni Abraham Kuriakose
Journal: Cancer Research (2014)

Abstract Background: Cross talk between the epidermal growth factor receptor (EGFR) and prostaglandin E2 pathways (PGE2) is well established. Activation of EGFR signaling can induce PGE2. Urinary PGE-M is a stable end metabolite of PGE2. The purpose of this study was to evaluate the role of urinary PGE-M as a biomarker predicting response to anti-EGFR monoclonal antibody therapy in patients with head and neck squamous cell carcinoma (HNSCC). Patients and Methods: Ten HNSCC patients with recurrent and/or metastatic disease received Nimotuzumab, a humanized monoclonal antibody against EGFR. The response to Nimotuzumab was assessed 2 weeks following the fourth cycle using PERCIST criteria. Urine samples were collected before treatment and 2 weeks after the fourth cycle of therapy. Results: Seven patients had progressive disease (PD) while two patients had stable disease (SD) and one patient had a partial response (PR) to therapy. The mean pretreatment value of urinary PGE-M in patients with SD or PR was 63 ng/mg Cr (range 48-78 ng/mg Cr). By comparison, patients with progressive disease had lower baseline levels of urinary PGE-M with mean pretreatment value of 37ng/mg Cr (range 15- 54ng/mg Cr). More than a 20% reduction in post treatment vs. pretreatment urinary PGE-M values was seen in patients with SD and PR. By comparison, patients with progressive disease had either a minimal reduction or an increase in the post treatment levels of urinary PGE-M. Conclusion: Elevated pretreatment levels of urinary PGE-M may predict response to anti-EGFR therapy in patients with HNSCC. These findings need further validation. Citation Format: Vikram D. Kekatpure, Amritha Suresh, Bharath Rangarajan, Gangotri Siddappa, Moni Abraham Kuriakose. Urinary prostaglandin E metabolite as a biomarker predicting response to EGFR therapy in patients with head and neck cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2848. doi:10.1158/1538-7445.AM2014-2848
Viral hepatitis, HIV, human herpes virus and Treponema pallidum infection in haemodialysis patients from Kosovo, 2005
Authors: G L Quaglio, C Pattaro, N Ramadani, L Bertinato, Y Elezi, P Dentico, A Volpe, M Ciotti, G Rezza, G Putoto
Journal: Eurosurveillance (2009)

Binary file ES_Abstracts_Final_ECDC.txt matches
Pneumatosis Cystoides Intestinalis
Authors: Shun-Sheng Wu, Hsu-Heng Yen
Journal: New England Journal of Medicine (2011)

An asymptomatic 67-year-old woman undergoing screening colonoscopy was found to have multiple translucent polypoid lesions in the wall of the ascending colon. CT imaging revealed a honeycomb-like cluster of air-filled sacs within the right colonic wall.
Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa
Authors: Tania M. Gonzalez Santiago, Andrey Zavialov, Janna Saarela, Mikko Seppanen, Ann M. Reed, Roshini S. Abraham, Lawrence E. Gibson
Journal: JAMA Dermatology (2015)

Mutations in the CERC1 gene associated with deficiency in the ADA2 protein (DADA2) have been implicated in the pathogenesis of cutaneous polyarteritis nodosa (cPAN) and early-onset vasculopathy. DADA2 is not only limited to cPAN and vasculopathy but also includes immunodeficiency that affects several cellular compartments, including B cells; however, some patients appear to have a more indolent, skin-limited disease.In this report, we describe 2 white siblings (female and male) with a history of cPAN with DADA2 as a result of novel compound heterozygous mutations inherited in trans in the CECR1 gene (c.37_39del [p.K13del] and c.1159C>A [p.N328K]). The onset of disease was earlier in the female sibling than the male sibling although both were diagnosed as having cPAN in early childhood. The disease is associated with a more significant immunodeficiency and other systemic symptoms in the female than the male sibling.These findings suggest a genetic cause of cPAN in some patients. Therefore, DADA2 should be considered in patients with cPAN, specifically in those whose conditions are diagnosed at an early age, regardless of their ethnicity, presence or absence of systemic symptoms, or a family history of the disease.